On Thursday, Novavax Inc. (NASDAQ:NVAX) reported first-quarter 2025 sales of $667 million, compared to $94 million a year ago, beating the consensus of $343.85 million. Higher product sales for the first quarter of 2025 were primarily due to $603 million of revenue recognized with the termination…
Continue reading...